John Leonard, MD, Discusses the Future of the Treatment Landscape for MCL
In the third installment of this 3-part podcast series, John Leonard, MD, Physician and Professor, Weill Cornell Medicine and NewYork-Presbyterian Hospital, discusses the future outlook of the treatment landscape for mantle cell lymphoma (MCL).
I'm excited and optimistic about the treatment landscape for MCL. I think that this is an area where the focus on mantle cell and the understanding of mantle cell specifically as a disease, the clinical presentations and clinical characteristics as well as the biologic characteristics and targets have led to a tremendous amount of progress. I think we now know much more about the preferred chemotherapy treatment options if a patient is going in that direction. We know that adding new targets, new targeted agents, may improve outcomes in certain situations or that swapping in targeted agents (particularly Bruton’s tyrosine kinase inhibitors, lenalidomide, anti-CD20 antibodies) can offer an alternative for patients with mantle cell.
I think that we now know that we have novel agents that can be active and effective in patients with resistance or refractory disease and I think we're learning more and more about how to deploy these agents in what clinical settings as well as in what combinations.
And then I think stem-cell transplant remains something that is an option that is sometimes used in MCL and has some value to subsets of patients. And I think with the CAR T-cell era coming along we are learning more and more about the role of CAR T-cells and B-cell malignancies. We don't have extensive data right now with mantle cell but I would expect in the near future the CAR T-cell therapy will be something that we know a lot more about and could potentially have value to patients as well.